Deucravacitinib

(Sotyktu)

Deucravacitinib

Drug updated on 11/15/2023

Dosage FormTablet (oral; 6 mg)
Drug ClassTyrosine kinase 2 (TYK2) inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.